POPULATION PHARMACOKINETICS OF NIVOLUMAB IN JAPANESE PATIENTS WITH NON-SMALL CELL LUNG CANCER.

被引：0
|
作者：
Tohi, M. [1 ]
Mizuno, T. [2 ,3 ]
Irie, K. [1 ,4 ]
Okuyoshi, H. [1 ]
Hirabatake, M. [1 ]
Ikesue, H. [1 ]
Muroi, N. [1 ]
Eto, M. [1 ]
Tomii, K. [1 ]
Hashida, T. [1 ]
Fukushima, S. [4 ]
机构：
[1] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan
[2] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[3] Univ Cincinnati Coll, Cincinnati, OH USA
[4] Kobe Gakuin Univ, Kobe, Hyogo, Japan
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-069
引用
收藏
页码：S97 / S97
页数：1
相关论文
共 50 条
  • [1] Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer
    Emoto-Yamamoto, Y.
    Iida, S.
    Kawanishi, T.
    Fukuoka, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (02) : 232 - 239
  • [2] Long term effect of nivolumab in patients with non-small cell lung cancer.
    Sprauten, Mette
    Flote, Vidar
    Brustugun, Odd Terje
    Helland, Aslaug
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
    Tohi, Makiko
    Irie, Kei
    Mizuno, Tomoyuki
    Okuyoshi, Hiroyuki
    Hirabatake, Masaki
    Ikesue, Hiroaki
    Muroi, Nobuyuki
    Eto, Masaaki
    Fukushima, Shoji
    Tomii, Keisuke
    Hashida, Tohru
    THERAPEUTIC DRUG MONITORING, 2023, 45 (01) : 110 - 116
  • [4] Effect of genetic polymorphisms on erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer.
    Saeki, Sho
    Sasaki, Jiichiro
    Iwamoto, Norihiro
    Inaba, Megumi
    Ushijima, Sunao
    Kishi, Hiroto
    Fujii, Shinji
    Semba, Hiroshi
    Kashiwabara, Kosuke
    Sakata, Shinya
    Kai, Yuki
    Tsubata, Yukari
    Isobe, Takeshi
    Endo-Tsukude, Chihiro
    Kohrogi, Hirotsugu
    Saito, Hideyuki
    Hamada, Akinobu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Population pharmacokinetics and pharmacogenomics of erlotinib: Effect of drug exposure on treatment outcomes in Japanese patients with non-small cell lung cancer.
    Fukudo, M.
    Ikemi, Y.
    Togashi, Y.
    Masago, K.
    Kim, Y. H.
    Mio, T.
    Mishima, M.
    Inui, K.
    Katsura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Circadian variation in nivolumab efficacy in patients with advanced non-small cell lung cancer.
    Karabou, Abdoulaye
    Bisseux, Laurence
    Pavese, Ida
    Collon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients
    Srinivasan, Meenakshi
    Chaturvedula, Ayyappa
    Fossler, Michael J.
    Patil, Anand
    Gota, Vikram
    Prabhash, Kumar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (09): : 1216 - 1224
  • [8] Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients
    Srinivasan, Meenakshi
    Chaturvedula, Ayyappa
    Fossler, Michael J.
    Patil, Anand
    Prabhash, Kumar
    Gota, Vikram
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S10 - S10
  • [9] Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer
    Gupta, Neeraj
    Pierrillas, Philippe B.
    Hanley, Michael J.
    Zhang, Steven
    Diderichsen, Paul M.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (06): : 731 - 744
  • [10] Nivolumab timing as a major survival predictor in patients with stage IV non-small cell lung cancer.
    Karaboue, Abdoulaye
    Collon, Thierry
    Bodiguel, Viviane
    Cucherousset, Joel
    Innominato, Pasquale
    Bouchahda, Mohamed
    Adam, Rene
    Levi, Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345